23andMe Holding Co.
NASDAQ:ME
23andMe Holding Co.
Research & Development
23andMe Holding Co.
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
23andMe Holding Co.
NASDAQ:ME
|
Research & Development
-$205.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CVS Health Corp
NYSE:CVS
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cigna Corp
NYSE:CI
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Research & Development
-$364.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
23andMe Holding Co.
Glance View
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.
See Also
What is 23andMe Holding Co.'s Research & Development?
Research & Development
-205.4m
USD
Based on the financial report for Mar 31, 2024, 23andMe Holding Co.'s Research & Development amounts to -205.4m USD.
What is 23andMe Holding Co.'s Research & Development growth rate?
Research & Development CAGR 5Y
-8%
Over the last year, the Research & Development growth was 8%. The average annual Research & Development growth rates for 23andMe Holding Co. have been -9% over the past three years , -8% over the past five years .
